Achillion Pharmaceuticals Inc (NASDAQ:ACHN) Shorted Shares Strengthened By 7.64%

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Corporate Logo

During Q2 2018 the big money sentiment increased to 1.38. That’s change of 0.43, from 2018Q1’s 0.95. 11 investors sold all, 29 reduced holdings as Achillion Pharmaceuticals, Inc. ratio improved. 39 grew stakes while 16 funds amassed stakes. Funds hold 105.68 million shares thus 1.67% less from 2018Q1’s 107.48 million shares.
Moreover, Bb Biotech Ag has 0.1% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 1.28M shs. Rock Springs Capital L P holds 2.35M shs. Dimensional Fund Advsrs Limited Partnership has 0.01% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 6.89M shs. Northern holds 0% or 1.61 million shs in its capital. Teacher Retirement Systems Of Texas accumulated 22,330 shs. California State Teachers Retirement Systems accumulated 208,095 shs. Ecor1 Cap Ltd Com, a California-based fund reported 3.89M shs. 617,800 are held by Rhenman And Partners Asset. Creative Planning holds 0% of its capital in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 119,476 shs. Metropolitan Life Insur New York invested in 46,206 shs. Td Asset reported 0% stake. Raymond James And Associates stated it has 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Prudential invested in 0% or 12,022 shs. Credit Suisse Ag has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). National Bank Of America Corp De invested in 0% or 416,817 shs.

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) had an increase of its short interest by 7.64%. It was published in December by FINRA the 6.14M short interest on ACHN. That’s 7.64% up from 5.70 million shares. Former ACHN’s position will need 5 days to restore. It has 1.30 million average volume. Achillion Pharmaceuticals Inc’s short interest float is 4.92%.

Ticker’s shares touched $3.11 during the last trading session after 0.64% change.Achillion Pharmaceuticals, Inc. has volume of 1.20 million shares. Since December 8, 2017 ACHN has declined 11.53% and is downtrending. The stock underperformed the S&P 500 by 27.15%.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally.The firm is worth $431.10 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial.Last it reported negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

For more Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news posted recently go to: Nasdaq.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Fool.com. The titles are as follows: “Implied Volatility Surging for Achillion (ACHN) Stock Options – Nasdaq” posted on December 03, 2018, “Achillion Appoints Paul Firuta Chief Operating Officer – GlobeNewswire” on September 10, 2018, “Achillion to Present at the Baird 2018 Global Healthcare Conference – GlobeNewswire” with a publish date: August 30, 2018, “Achillion Reports First Quarter 2018 Financial Results and Management Transition – GlobeNewswire” and the last “Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc. – Motley Fool” with publication date: June 22, 2018.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.